Compare BridgeBio Pharma Inc (BBIO) vs Crown Castle International Corp (CCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Crown Castle International Corp — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Crown Castle International Corp trades at $73.76 (market cap $31.32B). The key difference: Crown Castle International Corp is the larger of the two by market cap, and Crown Castle International Corp pays a 5.77% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | CCI | |
|---|---|---|
Market Cap | $16.61B | $31.32B |
Sector | Health | Real Estate |
52-Week High | $90.17 | $103.79 |
52-Week Low | $47.29 | $73.61 |
Enterprise Value | $18.16B | $53.68B |
Dividend Yield | — | 5.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Crown Castle (CCI) trades at $75.59, up 0.89% on the day, but technical indicators signal a bearish trend with the stock near recent lows. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, while revenue has declined from $7.0B in 2023 to $4.26B in 2025. Analyst consensus is split evenly between Buy and Hold with a $95.29 price target, suggesting potential upside. Recent news highlights strategic shifts, including the sale of its fiber business and a focus on U.S. tower operations.
The outlook for CCI hinges on execution of its pure-play tower strategy amid high debt levels and competitive pressures. Investment appeal lies in its 5.5% dividend yield and discounted valuation, but risks include declining revenue, negative shareholder equity, and sensitivity to interest rates. Wall Street sees value if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Crown Castle International Corp
Crown Castle International owns and leases roughly 40,000 cell towers in the United States. It also owns more than 85,000 route miles of fiber. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company's fiber is primarily leased by wireless service providers to set up small-cell network infrastructure and by enterprises for their internal connection needs. Crown Castle's towers and fiber are predominantly located in the largest U.S. cities. The company has a very concentrated customer base, with more than 70% of its revenue coming from the big three U.S. mobile carriers. Crown Castle operates as a real estate investment trust.
Read more on CCI →
